Compare W W Grainger Inc (GWW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs State Street SPDR S&P Biotech ETF — how do they compare? W W Grainger Inc trades at $1,289.79 (market cap $59.76B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: W W Grainger Inc is far larger — about 5.9× State Street SPDR S&P Biotech ETF's market cap, and W W Grainger Inc pays a 0.79% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 25 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GWW | XBI | |
|---|---|---|
Market Cap | $59.76B | $10.11B |
Volume | 186,697 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $1.40K | $169.55 |
52-Week Low | $918.18 | $104.99 |
Typical Hold Time | 25 Days | 38 Days |
Enterprise Value | $61.96B | — |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
W.W. Grainger (GWW) trades at $1,268.67, up 0.41% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong profitability with 47.92% ROE and 9.92% net margin, though valuation metrics appear elevated with a P/E of 32.34. Recent earnings show two consecutive beats, while analyst consensus leans heavily toward Hold (66.66%) with a $1,310 price target. The company continues strategic expansion with a new Oregon distribution center and technology acquisitions.
GWW presents a balanced outlook with solid fundamentals offset by premium valuation. The stock offers steady dividend growth as a Dividend King but faces headwinds from industrial sector challenges. Upside potential exists if earnings momentum continues, though current levels suggest limited near-term catalysts given the cautious analyst stance and technical resistance near $1,280-$1,303.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
